A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Baricitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms BRAVE I
- Sponsors Eli Lilly
- 10 Aug 2018 Status changed from not yet recruiting to recruiting.
- 07 Aug 2018 Status changed from planning to not yet recruiting.
- 23 Jul 2018 According to Eli lilly Media release, Lilly plans to initiate this trial in the second half of 2018.